Skip Navigation

Cardiovascular Research 1999 44(3):498-506; doi:10.1016/S0008-6363(99)00259-X
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sinnaeve, P.
Right arrow Articles by Janssens, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinnaeve, P.
Right arrow Articles by Janssens, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Gene therapy in the cardiovascular system: an update

Peter Sinnaevea,b, Olivier Varennea,c, Désiré Collena and Stefan Janssensa,b,*

aCenter for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU-Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
bCardiac Unit, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
cCardiac Unit, Hôpital Bichat, Paris, France

* Corresponding author. Tel.: +11-32-16-344-235; fax: +11-32-16-345-990 stefan.janssens{at}med.kuleuven.ac.be

This update reviews the remarkable progression in several cardiovascular gene transfer domains. The first chemical gene therapy protocols to stimulate angiogenesis in ischemic myocardium are discussed and both the great expectations as well as remaining hurdles are highlighted. In experimental models of restenosis and heart failure gene therapy shows promising results. Important questions regarding vector-related limitations and suboptimal in vivo delivery systems will require expeditious attention for gene therapy to become a more widely applicable option in cardiovascular diseases.

KEYWORDS Atherosclerosis; Gene therapy; Heart failure; Hypertension; Infection/inflammation; Thrombosis/embolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.